Polaryx Therapeutics (PLYX) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($99.7 million vs $90.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | RLYB |
|---|---|---|
| Share price | $2.00 | $17.02 |
| Market cap | $99.69M | $90.42M |
| 1-day change | 0.00% | +0.18% |
| YTD return | — | +210.13% |
| 1-year return | — | +284.72% |
| 5-year return | — | -86.29% |
| P/E ratio (TTM) | — | 2.13 |
| EPS (TTM) | $-0.14 | $8.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.91 | $17.57 |
| 52-week low | $1.85 | $3.67 |
| Distance from 52-week high | -95.91% | -3.15% |
| Analyst consensus | none | — |
| Avg. price target upside | +275.00% | — |
| Average volume | 76.41K | 21.23K |
| Shares outstanding | 49.85M | 5.31M |
| Employees | 2 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
PLYX vs RLYB FAQ
Which is bigger, Polaryx Therapeutics or Rallybio?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $99.69M compared with $90.42M for Rallybio (RLYB).
Are Polaryx Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.